Blog Archives - ABC Transfer®

Pharmaceutical Technical Training for GMP Compliance

Jasmine Ratodiarisoa — Mon, 29 Jun 2026 08:04:27 +0000

Technical training and pharmaceutical compliance: investing in people to ensure quality

Quality in the pharmaceutical industry starts with people

In the pharmaceutical and biotechnology industries, quality is not solely determined by equipment performance, facility design, or process robustness. It also depends on the knowledge, expertise, and commitment of the people who operate, maintain, and manage these highly regulated environments.

As regulatory expectations continue to evolve and patient safety remains the industry’s highest priority, continuous training has become a fundamental component of any successful quality strategy.

The European Good Manufacturing Practices (EU GMP) guidelines clearly recognize this reality. They emphasize that personnel must possess the appropriate education, training, and experience required to perform their assigned responsibilities effectively and consistently.

Far from being a simple regulatory obligation, training is a key driver of operational excellence, risk management, and long-term performance.

EU GMP: placing competence at the heart of quality systems

Chapter 2 of the EU GMP Guidelines focuses specifically on personnel and highlights the importance of initial and ongoing training throughout an employee’s professional journey.

This requirement extends across the entire pharmaceutical value chain, including:
• Production operators
• Maintenance technicians
• Process engineers
• Validation specialists
• Quality assurance professionals

External contractors and technical partners involved in critical operations.

The objective is straightforward: every individual involved in pharmaceutical manufacturing must understand not only what needs to be done, but also why it must be done in a specific way.

Competence is therefore a critical element in ensuring consistent product quality and regulatory compliance.

Training as a tool for risk reduction

Human error remains one of the most significant sources of deviations and operational issues in regulated environments.

Even the most advanced technologies cannot compensate for insufficient knowledge or inadequate understanding of procedures and equipment.

Well-structured technical training helps organizations:
• Reduce operational errors
• Improve process reliability
• Minimize deviations and corrective actions
• Increase equipment availability
• Strengthen regulatory compliance
• Enhance overall operational performance

Beyond procedural execution, effective training enables personnel to understand the rationale behind GMP requirements and the potential impact of non-compliance on product quality and patient safety.

This understanding is essential for developing a sustainable quality culture.

Keeping pace with technological evolution

The pharmaceutical industry is undergoing significant transformation. Advanced automation, digitalization, contamination control strategies, aseptic processing technologies, and increasingly stringent regulatory expectations are reshaping manufacturing environments.

As technologies evolve, so must the competencies required to operate them.

Organizations must ensure that their teams remain up to date with new equipment, processes, and regulatory expectations. Continuous learning is no longer optional; it is a strategic necessity.

Companies that invest in the development of their workforce are better positioned to improve efficiency, maintain compliance, and successfully navigate future industry challenges.

The importance of knowledge transfer

Successful pharmaceutical projects rely not only on selecting the right technologies but also on ensuring that those technologies are properly understood and utilized.

Equipment manufacturers, distributors, and technical partners play a crucial role in transferring the knowledge necessary for safe and efficient operation.

Training delivered during installation, commissioning, qualification, and operational phases helps users maximize equipment performance while maintaining compliance with applicable regulations.

Knowledge transfer therefore becomes an extension of the partnership between solution providers and pharmaceutical manufacturers.

ABC Transfer’s commitment to competence development

For many years, ABC Transfer has supported pharmaceutical, biotechnology, and life science companies with innovative aseptic transfer solutions designed for critical manufacturing environments.

Beyond supplying high-quality equipment and components, our teams regularly provide installation support, commissioning assistance, and on-site technical training to ensure that users can operate our solutions safely, efficiently, and in compliance with industry requirements.

Knowledge sharing has always been an integral part of our commitment to customers.

Contact us

As a member of the SKAN Group, a global leader in aseptic processing, containment technologies, and cleanroom solutions, ABC Transfer shares a common vision: operational excellence is achieved through the combination of advanced technologies and highly skilled professionals.

In line with this commitment, ABC Transfer recently organized the first edition of a dedicated technical training session for its distributors and technical partners.

The objective was to deepen product knowledge, share best practices, and strengthen understanding of the specific challenges faced by pharmaceutical and biotechnology manufacturers.

Beyond the technical content, the event provided an excellent opportunity for participants to exchange experiences, align knowledge levels, and reinforce a shared culture of quality, compliance, and customer support.

Building the skills needed for tomorrow’s pharmaceutical industry

The pharmaceutical industry continues to evolve at an unprecedented pace. Regulatory expectations are increasing, technologies are becoming more sophisticated, and quality requirements continue to rise.

In this environment, developing and maintaining competencies is essential for sustainable success.

Training is not simply an investment in people; it is an investment in quality, compliance, performance, and ultimately patient safety.

At ABC Transfer, we believe that sharing knowledge is a key contributor to long-term success. Through technical support, customer training, and initiatives such as our first distributor training session, we remain committed to helping our partners develop the expertise required to meet the challenges of tomorrow’s pharmaceutical industry.

L’article Pharmaceutical Technical Training for GMP Compliance est apparu en premier sur ABC Transfer®.

EU GMP Annex 1 (2022): Key changes and Impact on Sterile Manufacturing

Thierry Girard — Mon, 15 Sep 2025 09:55:09 +0000

What is Annex 1 of the European GMP?

Abstract

The 2022 revision of EU GMP Annex 1—effective from 25 August 2023, with certain provisions (e.g., lyophilizer requirements) effective from 25 August 2024—constitutes a major transformation in sterile product manufacturing. This paper presents a structured, in-depth analysis of the key changes, including the emphasis on Quality Risk Management (QRM) and Contamination Control Strategy (CCS), cleanroom classifications, advanced barrier technology (RABS and isolators), and digitalization. It further explores the specific implications for pharmaceutical firms and barrier system manufacturers, drawing on SKAN’s expertise in isolator design, decontamination, and automation to illuminate practical implementation.

1. Introduction

Sterile medicinal products demand rigorous microbial, particulate, and pyrogen contamination control to guarantee patient safety. EU GMP Annex 1, “Manufacture of Sterile Medicinal Products,” provides regulatory guidance for this purpose. The 2022 revision—crafted collaboratively by the European Commission, PIC/S [12], and WHO [10]—significantly updates expectations, adding clarity, scope, and alignment with modern technological and process capabilities. These revisions underscore risk-based frameworks, contamination control strategies, and advanced barrier technologies [1]. This article unpacks those changes and explores their consequences for the pharmaceutical industry, with concrete examples related to SKAN’s isolator technologies [9].

2. Overview of EU GMP Annex 1 (2022 Revision)

2.1 Scope and Rationale

Published 25 August 2022 and enforceable from 25 August 2023 (with Section 8.123 phased in August 2024), the revision reflects technological advances and regulatory harmonization across EMA [11], PIC/S [12], and WHO [10]. Highlights include expansion from ~16 to over 50 pages, broader scope including non-sterile areas where contamination risks are relevant [4], and alignment with ISO 14644, ICH Q8/Q9/Q10, and lifecycle management [3].

2.2 Core Principles

– Quality Risk Management (QRM): Mandatory across all EU GMP Annex 1 domains—from facility design to process validation [1].
– Contamination Control Strategy (CCS): Central requirement. CCS must unify risk assessments, premises, equipment, personnel, monitoring, and corrective actions into a coherent, documented plan [3].
– Barrier Technologies: RABS and isolators are strongly encouraged. Their absence requires justification in the CCS [5].

Discover secure transfer systems from ABC Transfer®

2.3 Focused Updates

Key areas of change include revised cleanroom classifications [5], PUPSIT requirements [3], stricter gowning [3], enhanced utility controls [2], and encouragement of robotics and digitalization [1][6].

3. Implications for Drug Manufacturers

3.1 Implementing a CCS under EU GMP Annex 1

Manufacturers must develop a CCS integrating QRM findings, facility design, environmental controls, personnel behavior, equipment maintenance, media fills, and monitoring programs. The CCS must be periodically reviewed in management reviews [1][3].

3.2 PQS Integration

The PQS must embed EU GMP Annex 1 expectations, ensuring linkage between risk assessments and change control decisions, end-to-end traceability, and governance of residual risk justification [7].

3.3 Facility and Barrier Technology

EU GMP Annex 1 strongly favors barrier technologies. RABS and isolators provide enclosed Grade A zones with better contamination control. Manufacturers upgrading older lines to closed RABS achieve compliance with limited investment [5][9].

3.4 Personal & Training

Sterility assurance emphasizes controlling human contamination. Gowning protocols (socks, goggles, glove sanitization) must be enforced [3]. Operators must be trained and requalified annually per operator and line [8].

3.5 Utilities

Facilities must ensure continuous monitoring (e.g., TOC in WFI), sterilizing filtration for gases, and biofilm control in water systems [2].

3.6 Monitoring, APS & Digitalization

Environmental monitoring includes stricter alert/action levels and continuous monitoring for Grade A zones [8]. APS must be conducted semi-annually per filling line and operator [3]. Automated monitoring is encouraged [6].

4. Implications for RABS and Isolator Manufacturers

4.1 Regulatory Positioning

EU GMP Annex 1 positions isolators and RABS as favored technologies. Any alternative approaches must be justified [5].

4.2 Design & Engineering Requirements (SKAN insights)

Key requirements include hygienic design, smooth interior surfaces for cleaning, validated VHP decontamination, and automation to reduce human interventions [9].
Differences:
– RABS: Grade B, occasional opening.
– Isolators: Grade D, fully enclosed, VHP decontamination, higher sterility [9].

4.3 Integrity and Airflow

For OEB4/OEB5 isolators: Grade A unidirectional airflow with dual HEPA, validated VHP cycles, and periodic integrity testing [9].

4.4 Containement of Potent Agents

Isolators provide superior containment for toxic/biohazard substances, aligning with biosafety requirements [6][9].

4.5 Automation and Digital Trends

SKAN and others develop robotic and gloveless isolators, automated sampling, and digital integration, reducing human exposure and aligning with Annex 1 [6][9].

4.6 Retrofit and Modular Upgrades

SKAN offers modular isolators and RABS retrofits for existing lines, enabling validated decontamination, glove integrity testing, and compliance without full rebuilds [9].

4.7 Documentation, Validation & CCS Support

Providers must supply validation protocols, FAT/SAT and IQ/OQ/PQ documentation, monitoring instruments, and GMP training packages [9].

5. Strategic Recommendations & Examples

– Drug Manufacturer: Adopt isolators for high-risk operations; integrate QRM/CCS into PQS [9].
– Barrier System Provider: Prioritize hygienic, validated, automated designs [9].
– Operational Excellence: Replace manual settle plates with automated monitoring [6][9].
– Compliance Roadmap: Use CCS to justify interim solutions [7][9].

6. Conclusion

The 2022 revision of EU GMP Annex 1 reshapes sterile manufacturing by embedding QRM, CCS, and advanced technologies (RABS, isolators, automation). For drug manufacturers, this means integrated planning, facility upgrades, and continuous monitoring. For barrier system providers like SKAN, it means a pivotal role in enabling compliance through hygienic, decontaminable, automated, and validated solutions. Collaboration between regulators, manufacturers, and technology providers will be essential for ensuring sterility assurance [1][9].

References

1. ISPE – International Society for Pharmaceutical Engineering. https://ispe.org
2. NSF International. https://nsf.org
3. SciLife. https://scilife.io
4. Public Health Guidance Documents
5. GMP-Verlag Peither AG. https://gmp-verlag.de
6. PharmTech – Pharmaceutical Technology. https://www.pharmtech.com
7. RAPS – Regulatory Affairs Professionals Society. https://raps.org
8. QUALIA BioSafe Tech
9. SKAN AG. https://skan.com
10. World Health Organization (WHO). https://who.int
11. European Medicines Agency (EMA). https://ema.europa.eu
12. PIC/S – Pharmaceutical Inspection Co-operation Scheme. https://picscheme.org

L’article EU GMP Annex 1 (2022): Key changes and Impact on Sterile Manufacturing est apparu en premier sur ABC Transfer®.